Precursors T Cell + Limited by the Number of CD 8 an Antitumor Response , but Efficacy Is CD 4-Directed Peptide Vaccination Augments

[1]  M. Bevan,et al.  Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.

[2]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[3]  Vladimir Brusic,et al.  MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Martin A. Nowak,et al.  Compromised Influenza Virus-Specific CD8+-T-Cell Memory in CD4+-T-Cell-Deficient Mice , 2002, Journal of Virology.

[5]  B. Rocha,et al.  A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory , 2002, Science.

[6]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[7]  J. Sidney,et al.  Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. , 2002, Cancer research.

[8]  Francesco M Marincola,et al.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.

[9]  F. Marincola,et al.  Functional Heterogeneity of Vaccine-Induced CD8+ T Cells1 , 2002, The Journal of Immunology.

[10]  G. Schuler,et al.  Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells , 2002, The Journal of experimental medicine.

[11]  M. Cheever,et al.  Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Xiang,et al.  Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. , 2002, Cancer research.

[13]  G. Belz,et al.  Cutting Edge: Precursor Frequency Affects the Helper Dependence of Cytotoxic T Cells1 , 2002, The Journal of Immunology.

[14]  A. Ribas,et al.  CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. , 2001, Cancer research.

[15]  P. Coulie,et al.  A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[17]  S. Schoenberger,et al.  Stimulation via CD40 can substitute for CD4 T cell function in preventing reactivation of a latent herpesvirus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  G. Zeng,et al.  MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. , 2001, Journal of immunotherapy.

[19]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[20]  P. Srivastava,et al.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Speiser,et al.  Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[23]  G. Zeng.  MHC Class II-Restricted Tumor Antigens Recognized by CD4+ T Cells: New Strategies for Cancer Vaccine Design. , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[24]  B. Robinson,et al.  Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1 , 2000, The Journal of Immunology.

[25]  B. Fox,et al.  Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy1 , 2000, The Journal of Immunology.

[26]  F. Marincola,et al.  Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells , 2000, The Journal of Immunology.

[27]  R. Schreiber,et al.  Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.

[28]  O. Tsitsilonis,et al.  Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor , 2000, The Journal of Immunology.

[29]  Steven A. Rosenberg,et al.  Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice , 2000, The Journal of Immunology.

[30]  D. Pardoll,et al.  Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes , 2000, The Journal of experimental medicine.

[31]  S. Rosenberg,et al.  MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. , 1999, Cancer research.

[32]  A. Enk,et al.  Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.

[33]  S. Steinberg,et al.  Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. , 1999, Journal of immunology.

[34]  R. Schreiber,et al.  CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .

[35]  S. Rosenberg,et al.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.

[36]  J. Shabanowitz,et al.  Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.

[37]  J. Altman,et al.  Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.

[38]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[39]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[40]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[41]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[42]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[43]  C. Melief,et al.  Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.

[44]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[45]  A. Bernheim,et al.  Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. , 1998, Blood.

[46]  D. Hanahan,et al.  Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy , 1997, The Journal of experimental medicine.

[47]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[48]  R. Flavell,et al.  Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand , 1995, Nature.

[49]  P. Monach,et al.  A unique tumor antigen produced by a single amino acid substitution. , 1995, Immunity.

[50]  R. Schwartz,et al.  A subset of CD4+ thymocytes selected by MHC class I molecules. , 1994, Science.

[51]  H. Pircher,et al.  Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice , 1991, Cell.

[52]  P. Allen,et al.  T cell recognition of bovine ribonuclease. Self/non-self discrimination at the level of binding to the I-Ak molecule. , 1988, Journal of immunology.

[53]  M. Bevan,et al.  Introduction of soluble protein into the class I pathway of antigen processing and presentation , 1988, Cell.

[54]  P. Allen,et al.  Direct evidence for functional self-protein/Ia-molecule complexes in vivo. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[55]  B. Kyewski,et al.  CD4+ helper T cells are required for resistance to a highly metastatic murine tumor , 1987, European journal of immunology.

[56]  Alessandro Sette,et al.  Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells , 1987, Nature.

[57]  E. Unanue,et al.  Differential requirements for antigen processing by macrophages for lysozyme-specific T cell hybridomas. , 1984, Journal of immunology.

[58]  A. Deleo,et al.  Mouse. I. Murine leukemia virus-related antigens and allo- antigens on cultured fibroblasts and sarcoma cells. Description of a unique antigen on balb/c meth a sarcoma. , 1977 .